Detalhe da pesquisa
1.
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
JAMA
; 331(17): 1460-1470, 2024 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38581198
2.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
3.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
4.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
5.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
6.
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
BJU Int
; 130(3): 370-380, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373443
7.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med
; 377(4): 338-351, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578639
8.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355464
9.
Correction: YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells.
J Transl Med
; 22(1): 20, 2024 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38178184
10.
Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study.
BMC Cancer
; 19(1): 947, 2019 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31615476
11.
Urinary, bowel and sexual health in older men from Northern Ireland.
BJU Int
; 122(5): 845-857, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29489050
12.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet
; 387(10024): 1163-77, 2016 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26719232
13.
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Lancet Oncol
; 17(2): 243-256, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26718929
14.
EPLIN: a fundamental actin regulator in cancer metastasis?
Cancer Metastasis Rev
; 34(4): 753-64, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26350886
15.
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
BJU Int
; 118(6): 869-879, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27415448
16.
Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation.
J Immunol
; 192(7): 3101-10, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24600032
17.
Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan™) platform.
Mol Cell Proteomics
; 13(4): 1050-64, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24505114
18.
YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells.
J Transl Med
; 13: 280, 2015 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-26310485
19.
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
BJU Int
; 116(6): 880-7, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25639506
20.
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Lancet Oncol
; 15(10): 1109-18, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25163905